Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).

Shah RB, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W.

Prostate. 2019 Aug;79(11):1267-1273. doi: 10.1002/pros.23831. Epub 2019 May 21.

PMID:
31111513
2.

Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.

Shah RB, Nguyen JK, Przybycin CG, Reynolds JP, Cox R, Myles J, Klein E, McKenney JK.

Histopathology. 2019 Sep;75(3):346-353. doi: 10.1111/his.13878. Epub 2019 Jul 2.

PMID:
31012493
3.

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.

Oncogene. 2019 Jun;38(23):4496-4511. doi: 10.1038/s41388-019-0732-7. Epub 2019 Feb 11.

4.

An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.

Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S.

Nat Cell Biol. 2019 Feb;21(2):203-213. doi: 10.1038/s41556-018-0260-7. Epub 2019 Jan 21.

5.

Impact of collaboration between psychologists and dermatologists: UK hospital system example.

Shah RB.

Int J Womens Dermatol. 2017 Nov 26;4(1):8-11. doi: 10.1016/j.ijwd.2017.10.003. eCollection 2018 Mar. Review.

6.

Ferrofluid lubrication of circular squeeze film bearings controlled by variable magnetic field with rotations of the discs, porosity and slip velocity.

Shah RC, Shah RB.

R Soc Open Sci. 2017 Dec 13;4(12):170254. doi: 10.1098/rsos.170254. eCollection 2017 Dec.

7.

Reply to 'Low-grade intraductal carcinoma of the prostate: an idea whose time has not yet come': evidence-based medicine suggests that the time is now.

Shah RB.

Histopathology. 2017 Nov;71(5):839-840. doi: 10.1111/his.13302. Epub 2017 Sep 8. No abstract available.

PMID:
28670692
8.

Anesthetic Management of a Parturient with Severe Pulmonary Restenosis Posted for Cesarean Section.

Shah RB, Butala BP, Parikh GP.

Anesth Essays Res. 2017 Apr-Jun;11(2):517-519. doi: 10.4103/0259-1162.194570.

10.

NPM1 directs PIDDosome-dependent caspase-2 activation in the nucleolus.

Ando K, Parsons MJ, Shah RB, Charendoff CI, Paris SL, Liu PH, Fassio SR, Rohrman BA, Thompson R, Oberst A, Sidi S, Bouchier-Hayes L.

J Cell Biol. 2017 Jun 5;216(6):1795-1810. doi: 10.1083/jcb.201608095. Epub 2017 Apr 21.

11.

GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall.

Tian W, Dorn D, Wei S, Sanders RD, Matoso A, Shah RB, Gordetsky J.

Histopathology. 2017 Jul;71(1):150-155. doi: 10.1111/his.13214. Epub 2017 Apr 26.

PMID:
28316088
12.

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.

Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T.

Cancer Lett. 2017 May 28;394:52-64. doi: 10.1016/j.canlet.2017.02.023. Epub 2017 Feb 27.

PMID:
28254410
13.

Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.

Hickman RA, Yu H, Li J, Kong M, Shah RB, Zhou M, Melamed J, Deng FM.

Am J Surg Pathol. 2017 Apr;41(4):550-556. doi: 10.1097/PAS.0000000000000794.

PMID:
28009609
14.

Anesthesia in a patient with gitelman syndrome.

Shah RB, Shah VR, Parikh GP, Vora KS.

J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):405-6. doi: 10.4103/0970-9185.173359. No abstract available.

15.

Erratum to: Modified Atkins diet in advanced malignancies-final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System.

Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, Shah RB.

Nutr Metab (Lond). 2016 Sep 1;13(1):61. doi: 10.1186/s12986-016-0120-z. eCollection 2016.

16.

Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System.

Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, Shah RB.

Nutr Metab (Lond). 2016 Aug 12;13:52. doi: 10.1186/s12986-016-0113-y. eCollection 2016. Erratum in: Nutr Metab (Lond). 2016;13(1):61.

17.

Improvement of diagnostic agreement among pathologists in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies using a novel "Disease-Focused Diagnostic Review" quality improvement process.

Shah RB, Leandro G, Romerocaces G, Bentley J, Yoon J, Mendrinos S, Tadros Y, Tian W, Lash R.

Hum Pathol. 2016 Oct;56:155-62. doi: 10.1016/j.humpath.2016.06.009. Epub 2016 Jun 23.

PMID:
27346573
18.

A mitosis-sensing caspase activation platform? New insights into the PIDDosome.

Shah RB, Thompson R, Sidi S.

Mol Cell Oncol. 2015 Jul 6;3(3):e1059921. doi: 10.1080/23723556.2015.1059921. eCollection 2016 May.

19.

Insulin delivery methods: Past, present and future.

Shah RB, Patel M, Maahs DM, Shah VN.

Int J Pharm Investig. 2016 Jan-Mar;6(1):1-9. doi: 10.4103/2230-973X.176456. Review.

20.

Recent advances in prostate cancer pathology: Gleason grading and beyond.

Shah RB, Zhou M.

Pathol Int. 2016 May;66(5):260-72. doi: 10.1111/pin.12398. Epub 2016 Mar 18. Review.

PMID:
26991008
21.

Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction.

Trivedi VR, Satia MC, Deschamps A, Maquet V, Shah RB, Zinzuwadia PH, Trivedi JV.

Nutr J. 2016 Jan 8;15:3. doi: 10.1186/s12937-016-0122-8.

22.

ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.

Shah RB, Li J, Dhanani N, Mendrinos S.

Urol Oncol. 2016 Mar;34(3):120.e1-7. doi: 10.1016/j.urolonc.2015.10.008. Epub 2015 Nov 14.

PMID:
26585946
23.

Intermittent exotropia: Surgical treatment strategies.

Kelkar JA, Gopal S, Shah RB, Kelkar AS.

Indian J Ophthalmol. 2015 Jul;63(7):566-9. doi: 10.4103/0301-4738.167109. Review.

24.

Primary Anal Canal Syphilis in Men: The Clinicopathologic Spectrum of an Easily Overlooked Diagnosis.

Gopal P, Shah RB.

Arch Pathol Lab Med. 2015 Sep;139(9):1156-60. doi: 10.5858/arpa.2014-0487-OA.

PMID:
26317454
25.

Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent.

Begley LA, Kasina S, Shah RB, Macoska JA.

Am J Clin Exp Urol. 2015 Aug 8;3(2):91-9. eCollection 2015.

26.

Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy: An Interobserver Reproducibility Study Among Urologic Pathologists With Recommendations.

Zhou M, Li J, Cheng L, Egevad L, Deng FM, Kunju LP, Magi-Galluzzi C, Melamed J, Mehra R, Mendrinos S, Osunkoya AO, Paner G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang X, Shah RB.

Am J Surg Pathol. 2015 Oct;39(10):1331-9. doi: 10.1097/PAS.0000000000000457.

PMID:
26099009
27.

Anesthetic management of renal transplantation in glucose-6-phosphate dehydrogenase-deficient patient.

Shah RB, Shah VR, Butala BP, Parikh GP.

Saudi J Kidney Dis Transpl. 2015 May-Jun;26(3):589-91. doi: 10.4103/1319-2442.157403. No abstract available.

28.

An Inhibitor of PIDDosome Formation.

Thompson R, Shah RB, Liu PH, Gupta YK, Ando K, Aggarwal AK, Sidi S.

Mol Cell. 2015 Jun 4;58(5):767-79. doi: 10.1016/j.molcel.2015.03.034. Epub 2015 Apr 30.

29.

Diagnosis of Gleason pattern 5 prostate adenocarcinoma on core needle biopsy: an interobserver reproducibility study among urologic pathologists.

Shah RB, Li J, Cheng L, Egevad L, Deng FM, Fine SW, Kunju LP, Melamed J, Mehra R, Osunkoya AO, Paner GP, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, Zhou M.

Am J Surg Pathol. 2015 Sep;39(9):1242-9. doi: 10.1097/PAS.0000000000000442.

PMID:
25929349
30.

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.

Shah RB, Bentley J, Jeffery Z, DeMarzo AM.

Hum Pathol. 2015 May;46(5):698-706. doi: 10.1016/j.humpath.2015.01.008. Epub 2015 Jan 29.

PMID:
25724568
31.

Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.

Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, Shah RB, Epstein JI, De Marzo AM, Lotan TL.

Am J Surg Pathol. 2015 Feb;39(2):169-78. doi: 10.1097/PAS.0000000000000348.

32.

Effect of intraoperative human albumin on early graft function in renal transplantation.

Shah RB, Shah VR, Butala BP, Parikh GP.

Saudi J Kidney Dis Transpl. 2014 Nov;25(6):1148-53.

33.

Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG.

Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.

PMID:
25263387
34.
35.

A biomimetic approach to active self-microencapsulation of proteins in PLGA.

Shah RB, Schwendeman SP.

J Control Release. 2014 Dec 28;196:60-70. doi: 10.1016/j.jconrel.2014.08.029. Epub 2014 Sep 8.

36.

Injectable controlled release depots for large molecules.

Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS.

J Control Release. 2014 Sep 28;190:240-53. doi: 10.1016/j.jconrel.2014.05.057. Epub 2014 Jun 12. Review.

37.

Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.

Shah RB, Yang Y, Khan MA, Raw A, Yu LX, Faustino PJ.

Int J Pharm. 2014 Apr 10;464(1-2):46-52. doi: 10.1016/j.ijpharm.2014.01.008. Epub 2014 Jan 17.

PMID:
24440404
38.

Spontaneous Closure of a Full-Thickness Stage 2 Idiopathic Macular Hole without Posterior Vitreous Detachment.

Kelkar AS, Bhanushali DR, Kelkar JA, Shah RB, Kelkar SB.

Case Rep Ophthalmol. 2013 Oct 23;4(3):188-91. doi: 10.1159/000356125. eCollection 2013.

39.

Impact of controlled ice nucleation on process performance and quality attributes of a lyophilized monoclonal antibody.

Awotwe-Otoo D, Agarabi C, Read EK, Lute S, Brorson KA, Khan MA, Shah RB.

Int J Pharm. 2013 Jun 25;450(1-2):70-8. doi: 10.1016/j.ijpharm.2013.04.041. Epub 2013 Apr 22.

PMID:
23618961
40.

Oseltamivir phosphate-amberlite(TM) IRP 64 ionic complex for taste masking: preparation and chemometric evaluation.

Siddiqui A, Shah RB, Khan MA.

J Pharm Sci. 2013 Jun;102(6):1800-1812. doi: 10.1002/jps.23518. Epub 2013 Apr 5.

PMID:
23559456
41.

Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.

Shah RB.

Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Review.

PMID:
23399797
42.

Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.

Yang Y, Bykadi S, Carlin AS, Shah RB, Yu LX, Khan MA.

J Pharm Sci. 2013 Apr;102(4):1370-81. doi: 10.1002/jps.23454. Epub 2013 Jan 18.

PMID:
23334989
43.

In vitro bioequivalence approach for a locally acting gastrointestinal drug: lanthanum carbonate.

Yang Y, Shah RB, Yu LX, Khan MA.

Mol Pharm. 2013 Feb 4;10(2):544-50. doi: 10.1021/mp300517p. Epub 2013 Jan 4. Review.

PMID:
23249191
44.

The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.

Shah RB, Tadros Y, Brummell B, Zhou M.

Hum Pathol. 2013 May;44(5):786-94. doi: 10.1016/j.humpath.2012.06.024. Epub 2012 Nov 14.

PMID:
23158212
45.

Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.

Awotwe-Otoo D, Agarabi C, Wu GK, Casey E, Read E, Lute S, Brorson KA, Khan MA, Shah RB.

Int J Pharm. 2012 Nov 15;438(1-2):167-75. doi: 10.1016/j.ijpharm.2012.08.033. Epub 2012 Aug 25.

PMID:
22944306
46.

Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship.

Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, Zhou M, Vankalakunti M, Salles PG, Cabrera RA, Gown AM, Amin MB.

Am J Surg Pathol. 2012 Sep;36(9):1265-78.

PMID:
22895263
47.

Medication error: Subarachnoid injection of tranexamic acid.

Butala BP, Shah VR, Bhosale GP, Shah RB.

Indian J Anaesth. 2012 Mar;56(2):168-70. doi: 10.4103/0019-5049.96335.

48.

Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.

Shah RB, Zhou M.

Adv Anat Pathol. 2012 Jul;19(4):270-8. doi: 10.1097/PAP.0b013e31825c6c0e. Review.

PMID:
22692290
49.

Physicochemical characterization of complex drug substances: evaluation of structural similarities and differences of protamine sulfate from various sources.

Awotwe-Otoo D, Agarabi C, Keire D, Lee S, Raw A, Yu L, Habib MJ, Khan MA, Shah RB.

AAPS J. 2012 Sep;14(3):619-26. doi: 10.1208/s12248-012-9375-0. Epub 2012 Jun 8.

50.

Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.

Shah RB, Montgomery JS, Montie JE, Kunju LP.

Urol Oncol. 2013 Nov;31(8):1650-5. doi: 10.1016/j.urolonc.2012.04.009. Epub 2012 May 17.

PMID:
22608543

Supplemental Content

Support Center